78712-67-1

Basic information

• Product Name: (E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester
• Synonyms: (E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester;ZIRVAUOPXCOSFU-BQYQJAHWSA-N;Ozagrel Impurity 6
• CAS NO: 78712-67-1
• Molecular Formula: C₁₂H₁₃BrO₂
• Molecular Weight: 269.13
• Mol File: 78712-67-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester(78712-67-1)
• EPA Substance Registry System: (E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester(78712-67-1)

Safety Data

• Hazardous Substances Data: 78712-67-1(Hazardous Substances Data)

Usage

General Description

The chemical compound (E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester is an ethyl ester derivative of (E)-3-[p-Bromomethylphenyl]acrylic acid. It is a synthetic organic compound that is commonly used in the field of organic chemistry and pharmaceutical research. It is known for its potential applications in the development of various pharmaceutical and medicinal products. The compound is also used as an intermediate in the synthesis of other organic compounds and plays a crucial role in the development of new chemical processes and methods. Its properties and reactivity make it a valuable component in the production of a wide range of chemical products.

Upstream product

• 128-08-5 N-Bromosuccinimide 
• 97585-04-1 ethyl (E)-3-(4-methylphenyl)acrylate 
• 873-55-2 sodium benzenesulfonate 
• 88738-86-7 methyl (E)-3-[4-(bromomethyl)phenyl]prop-2-enoate 

Downstream Products

• 1115433-99-2 ethyl (E)-4-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methyl]cinnamate 
• 74002-88-3 ethyl p-(1-imidazolylmethyl) cinnamate 
• 103549-17-3 3-[p-(1H-imidazole-1-ylmethyl)phenyl]propionic acid 
• 82571-53-7 ozagrel 
• 74003-01-3 4-[p-(1-imidazolylmethyl)phenyl] butyric acid hydrochloride 
• 74002-97-4 ethyl 3-<4-(1-imidazolylmethyl)phenyl>propionate 
• 74003-15-9 4-[p-(1-imidazolylmethyl)phenyl]butyronitrile 
• 74002-98-5 3-[4-(Imidazol-1-ylmethyl)phenyl]propanol 
• 74003-16-0 3-<4-(1-imidazolylmethyl)phenyl>propyl chloride 

Relevant articles and documents

Preparation method of Ozagrel sodium

The invention discloses a preparation method of Ozagrel sodium. The method comprises the following steps: performing a bromination reaction on ethyl 4-methylcinnamate and N-bromo-succinimide by takingacetonitrile as a solvent under the triggering of azodiisobutyronitrile, so as to obtain ethyl 4-bromomethylcinnamate; performing a condensation cyclization reaction on the ethyl 4-bromomethylcinnamate and imidazole by taking sodium hydroxide as an acid-binding agent and taking tetrahydrofuran as a solvent, so as to obtain imidazole ethyl 4-methylcinnamate; performing alkali hydrolysis on the imidazole ethyl 4-methylcinnamate, so as to obtain the Ozagrel sodium. According to the preparation method, the condensation cyclization reaction is performed by taking the sodium hydroxide as the acid-binding agent and taking the tetrahydrofuran as the solvent, so that the finally obtained product does not contain toxic components, the yield and the purity of the product can be effectively improved,and the content of genotoxic impurities (the ethyl 4-bromomethylcinnamate and ethyl 4-dibromomethylcinnamate) in the product is zero.

Sulfone compounds

The invention relates to novel sulfone compounds of formula I STR1 wherein R1 is an unsubstituted or substituted phenyl or naphthyl radical, R2 is hydrogen or the radical of the formula STR2 R3 and R4 are --CN o

Interphenylene 11,12-secoprostaglandins

Novel interphenylene derivatives of 11,12-secoprostaglandins are prepared by the stepwise alkylation of the ethyl ester or the t-butyl ester of acetoacetic acid. One such method involves treatment of the t-butyl ester of acetoacetic acid with a strong base to form the anion followed by treatment with ethyl p-(3-bromopropyl)benzoate to produce ethyl 4-(4-tert-butoxycarbonyl-5-oxo-hexyl)benzoate, subsequently reacting the anion of the thus-formed benzoate with 1-chloro-4-acetoxynonane to produce ethyl 4-(4-acetyl-4-tert-butoxycarbonyl-8-acetoxytridecyl)benzoate followed by decarboxylation and alkaline hydrolysis to produce the desired product 4-(4-acetyl-8-hydroxytridecyl)benzoic acid which is useful as a pharmaceutical in the treatment of patients with renal failure and in the prevention of transplant rejection.